BPPV Is Having a Moment on TikTok — Here's What the 2026 Evidence Actually Says About Treating It

Dizzy patients have always found their way into orthopedic and general caseloads, but lately they're finding their way to us with homework already done. Vestibular content — BPPV explainers, "do this if the room is spinning" videos, balance drills filmed on foam pads — has been racking up views on TikTok and Instagram, and there's a growing lineup of podcasts dedicated to vestibular rehab specifically. Patients are showing up having already watched a repositioning maneuver performed by a stranger online, sometimes before they've seen anyone in person for it.

That's not a bad thing. But it does raise the bar on us knowing, precisely, what the current evidence actually supports — and honestly, "which maneuver is best" is messier than a lot of patient-facing content makes it look. There's also a newer wrinkle about who responds to vestibular rehab (VRT) at all that's worth building into your evals.

The maneuver question: real agreement, and one genuine disagreement worth explaining to patients

A 2025 network meta-analysis in BMC Neurology pooled 22 RCTs and 2,507 patients comparing Epley, Semont, Brandt-Daroff, Gufoni, Gans, Modified Epley, and Self-Epley against untreated control, using remission rate as the outcome. The clean part of the result: every active maneuver beat doing nothing (Epley OR 7.9, Semont OR 6.1, Gufoni OR 5.1 vs. untreated control). The less clean part: the highest point estimate went to the Gans repositioning maneuver (OR 11, SUCRA 71.5%), followed by Modified Epley (SUCRA 68%) and Self-Epley (SUCRA 67.8%) — with standard Epley and Semont ranked below those less commonly used variants.

A few things worth knowing before you lean on this for patient education

The authors flagged a real risk of publication bias on funnel-plot analysis and called for larger, multicenter RCTs before treating any of these rankings as settled.

A second analysis, and the disagreement gets more interesting — it may be about timing

A 2022 network meta-analysis in Otology & Neurotology asked a related but genuinely different question: it measured outcomes separately at 1 week and 1 month, using an objective outcome (elimination of nystagmus on repeat Dix-Hallpike testing) across 41 RCTs and 12 treatment types — including EVR (Epley combined with vestibular rehab exercises) and a "Hybrid" maneuver.

The result is worth sitting with: at 1 week, EVR ranked best (SUCRA 77.5%), with Epley, Semont, and Hybrid also effective. But by 1 month, only Epley and Semont were still statistically effective — and the ranking flipped, with Semont overtaking Epley (SUCRA 76.1% vs. 65.3%). EVR and Hybrid's short-term edge didn't hold up over time. Two subgroup findings are worth knowing too: in patients under 55, Epley and Semont performed comparably (RR 0.99), and — this is the one to actually build into your intake — in patients with a longer duration of symptoms before treatment, Epley performed no better than sham (RR 1.07, CI crossing 1). That's consistent with either a real loss of efficacy from delayed treatment or with spontaneous resolution muddying the picture in longer-duration studies, but either way it's a reason not to sit on a BPPV referral.

Put the two analyses together and here's the honest state of the evidence: every commonly used maneuver clearly beats doing nothing, and Epley and Semont are both consistently strong performers. Which single maneuver "wins" a head-to-head varies by comparator set, outcome definition, and — per the 2022 study — possibly by how long after treatment you're measuring. That's a more useful, more honest thing to tell a patient than false precision about one "best" technique.

A maneuver variant worth knowing: Semont-plus

One more piece worth having in your back pocket: a 2023 randomized clinical trial in JAMA Neurology — 195 patients across three European referral centers — compared standard Epley against a modified technique called Semont-plus (the regular Semont maneuver plus an added head-shaking component) for posterior canal BPPV canalolithiasis specifically.

The headline result was about speed, not just success: patients in the Semont-plus group reached "no positional vertigo attacks inducible" in a mean of 2.0 days (median 1) versus 3.3 days (median 2) for standard Epley — a statistically significant difference. Interestingly, when they looked at the narrower question of single-maneuver success rate, there was no significant difference (68.4% Semont-plus vs. 62.9% Epley). No serious adverse effects in either group, and nausea rates were similar.

Practical takeaway: standard Epley remains a completely reasonable default, but if you're looking for a way to get patients symptom-free faster — particularly ones who are anxious about repeat visits or traveling soon — Semont-plus has trial-level evidence behind it as a faster-resolving alternative, not just a theoretical variant.

The wrinkle: cognitive status changes how much a patient gets out of VRT

Yes! new research is showing that cognitive status can play a role!

.

This is the part I haven't seen covered much in PT-facing content yet, and it's from a study published this past May that's worth building into how you screen and set expectations.

Researchers in Athens followed 100 people, ages 40–65, referred for vestibular rehab for chronic dizziness or imbalance (BPPV, vestibular neuritis, Meniere's, vestibular migraine, and PPPD were all represented). Before starting an 8-week individualized home VRT protocol, everyone was screened with the Montreal Cognitive Assessment (MoCA) — 54 patients screened positive for mild cognitive impairment (MCI, MoCA < 26), 46 didn't.

Both groups improved significantly on dizziness severity (DHI) and functional gait (FGA) after the 8 weeks — that part was true regardless of cognitive status, and the effect sizes were large in both groups. But the magnitude of improvement diverged: the cognitively intact group improved significantly more on dizziness severity (p = 0.038), and patients without MCI were 2.3 times more likely to reach the minimally clinically important difference on the DHI (18 points) than patients with MCI. A regression model found age, symptom duration, and cognitive status all independently predicted how much a patient's dizziness improved. Gait outcomes, interestingly, weren't significantly different between groups — the cognitive effect showed up specifically in perceived dizziness, not in objective balance performance.

What this means practically: if you've got an MoCA (or even a quick cognitive screen) in your intake toolkit for patients over 40 presenting with chronic dizziness, it may be worth using it — not to exclude anyone from VRT, but to calibrate expectations and possibly build in more supervised sessions or slower progressions for patients who screen positive for MCI, rather than assuming a flat home exercise program will land the same way for everyone.

One nuance worth passing along to patients with lower education levels specifically: the same study found education level independently predicted both baseline and final DHI scores (patients with more education reported less dizziness burden at both points) — a reminder that self-reported outcome measures like the DHI carry some baseline bias worth being aware of when tracking progress.

What this means for your plan of care

So which Maneuver to pick? Epley? Semont? or Semont Plus?

Lead with Epley, Semont, or Semont-plus for posterior canal BPPV — all three have solid support, and none of the current evidence should push you toward Brandt-Daroff as a standalone.Exactly which of the three is "best" genuinely varies by study, outcome measured, and follow-up window — that's a fair thing to say to a patient rather than overselling certainty. If time-to-resolution matters for a given patient, Semont-plus has trial-level evidence for getting there faster than standard Epley.

Don't let referrals sit. The 2022 Otology & Neurotology subgroup signal (Epley losing its edge over sham in patients with longer pre-treatment symptom duration) is abstract-only and needs more research, but directionally it lines up with what you'd expect clinically — treat it as one more reason to get BPPV patients in and repositioned promptly rather than as a hard, confirmed number.

Screen cognitive status in patients over 40 with chronic dizziness, especially before prescribing an unsupervised home VRT program. It won't change whether you offer VRT, but it should change how you dose supervision and how you set expectations for time-to-improvement.

Don't oversell the "it'll definitely come back" or "it definitely won't come back" narrative around BPPV recurrence. The evidence genuinely isn't strong enough yet to make a confident claim either way — say that plainly rather than guessing.

Bottom line

The maneuver debate doesn't have one clean, single "best technique" answer — and that's actually a more honest thing to tell patients than what a lot of algorithm-fed content implies. What the evidence does support clearly: Epley, Semont, and their variants meaningfully beat doing nothing or relying on Brandt-Daroff alone, and getting patients in for repositioning promptly appears to matter. The genuinely newer finding worth building into your practice isn't about which technique to use, though — it's about who's sitting in front of you. Cognitive status appears to meaningfully change how much relief a patient gets from the exact same VRT protocol, which is exactly the kind of nuance that separates a generic home exercise handout from an actual plan of care.